数据挖掘分析SLC7A11在食管癌中的表达及通过P53/ROS通路调节细胞铁死亡的意义

doi:10.3969/j.issn.1004-616x.2020.02.008

癌变·畸变·突变 ›› 2020, Vol. 32 ›› Issue (2): 126-131.doi: 10.3969/j.issn.1004-616x.2020.02.008

数据挖掘分析SLC7A11在食管癌中的表达及通过P53/ROS通路调节细胞铁死亡的意义

熊英友, 杨丽, 方呈祥, 吴倩, 张微, 赵毅, 文静

湖北民族大学附属民大医院肿瘤科, 湖北恩施 445000

收稿日期:2019-10-30 修回日期:2020-02-28 出版日期:2020-03-30 发布日期:2020-04-10
通讯作者: 文静,E-mail:atous@qq.com E-mail:atous@qq.com
作者简介:熊英友,E-mail:xingfengkb207@163.com。
基金资助:
恩施州医疗卫生类指导性项目（JCY2019000029）

Data mining analysis of SLC7A11 expression in esophageal cancer and its involvement in regulating ferroptosis through the P53/ROS Metabolic Pathway

XIONG Yingyou, YANG Li, FANG Chengxiang, WU Qian, ZHANG Wei, ZHAO Yi, WEN Jing

Department of Oncology, Minda Hospital of Hubei Minzu University, Enshi 445000, Hubei, China

Received:2019-10-30 Revised:2020-02-28 Online:2020-03-30 Published:2020-04-10

摘要/Abstract

摘要： 目的： 分析溶质运载蛋白7家族成员11（SLC7A11）在食管癌（ESCA）组织中的表达与功能，及对患者生存预后的影响。方法： 基于Oncomine及GEPIA数据库，检索SLC7A11在ESCA组织与正常食管组织中的表达差异；采用GeneMANIA数据库构建有关SLC7A11的蛋白互作网络（PPI），并进行功能注释分析其共同富集的生物学功能；通过KEGG Pathway数据库分析其参与的信号通路；利用R2基因分析可视化平台，绘制Kaplan-Meier函数曲线，分析SLC7A11的表达对患者生存预后的影响。结果： Oncomine及GEPIA数据分析显示，SLC7A11在ESCA组织中mRNA的表达水平较正常组织显著升高（P < 0.05），且高表达组患者生存预后较差，差异具有统计学意义（P < 0.05）；SLC7A11与SLC3A2、BSG、ASNS、PHGDH、TERT、CD44等20种蛋白相互作用，主要富集于氨基酸转运、修饰氨基酸的跨膜转运活性、白细胞游走、多肽抗原绑定等生物学功能；SLC7A11通过P53/ROS信号的活化介导细胞铁死亡信号通路（hsa04216）的调节。结论： SLC7A11在ESCA组织中表达升高，且高表达组患者预后不良；SLC7A11可能通过P53、ROS代谢通路参与细胞铁死亡，有望成为ESCA患者早期诊断、治疗及判断预后的分子靶标。

关键词: 食管癌, 溶质运载蛋白7家族成员11, 数据挖掘, 铁死亡

Abstract: OBJECTIVE: To explore the expression and function of solute carrier family 7 member 11 (SLC7A11) in esophagus cancer (ESCA) and its prognostic value in patients. METHODS: Differences in expression of SLC7A11 in ESCA tissues and normal esophageal tissues were analyzed using the Oncomine and GEPIA databases. GeneMANIA database was used to construct the protein-protein interaction network (PPI) which is related to SLC7A11, and functional annotation was carried out to analyze its common enrichment functions. KEGG Pathway database was used to analyze the signaling pathways involved. Kaplan-Meier curve was drawn using the R2 gene analysis visualization platform to study the association of SLC7A11 expression and overall survival (OS) of ESCA patients. RESULTS: Based on the Oncomine and GEPIA databases,the mRNA expression levels of SLC7A11 in ESCA tissues were significantly higher than that in normal tissues,the prognosis of patients in the high-expression group was worse,and their differences were statistically significant (P < 0.05). SLC7A11 interacts with 20 proteins including SLC3A2, BSG, ASNS, PHGDH, TERT and CD44, and they were enriched in amino acid transport, modified amino acid transmembrane transporter activity, leukocyte migration,peptide antigen binding and other biological functions. SLC7A11 was involved in regulation of the ferroptosis (hsa04216) signaling pathway. CONCLUSION: SLC7A11 was up-regulated in ESCA significantly, indicative of poor prognosis, involved in ferroptosis through the P53 and ROS metabolic pathways. Therefore,SLC7A11 can be considered to be biomarkers for early diagnosis,treatment and prognosis of patients with ESCA.

Key words: esophagus cancer, SLC7A11, data mining, ferroptosis

中图分类号:

R735.1

熊英友, 杨丽, 方呈祥, 吴倩, 张微, 赵毅, 文静. 数据挖掘分析SLC7A11在食管癌中的表达及通过P53/ROS通路调节细胞铁死亡的意义[J]. 癌变·畸变·突变, 2020, 32(2): 126-131.

XIONG Yingyou, YANG Li, FANG Chengxiang, WU Qian, ZHANG Wei, ZHAO Yi, WEN Jing. Data mining analysis of SLC7A11 expression in esophageal cancer and its involvement in regulating ferroptosis through the P53/ROS Metabolic Pathway[J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2020, 32(2): 126-131.

参考文献

[1] TORRE L A, BRAY F, SIEGEL R L, et al. Global cancer statistics, 2012[J]. CA Cancer J Clin, 2015, 65(2):87-108.
[2] CHEN W Q. Cancer statistics:updated cancer burden in China[J]. Chung-Kuo Yen Cheng Yen Chiu, 2015, 27(1):1.
[3] LIM J K M, DELAIDELLI A, MINAKER S W, et al. Cystine/glutamate antiporter xCT (SLC7A11) facilitates oncogenic RAS transformation by preserving intracellular redox balance[J]. Proc Natl Acad Sci USA, 2019, 116(19):9433-9442.
[4] LEWERENZ J, HEWETT S J, HUANG Y, et al. The cystine/glutamate antiporter system x(c)(-) in health and disease:from molecular mechanisms to novel therapeutic opportunities[J]. Antioxid Redox Signal, 2013, 18(5):522-555.
[5] GALVÁN I, INÁCIO Â, DAÑINO M, et al. High SLC7A11 expression in normal skin of melanoma patients[J]. Cancer Epidemiol, 2019, 62:101582.
[6] GALVÁN I, INÁCIO Â, DAÑINO M, et al. High SLC7A11 expression in normal skin of melanoma patients[J]. Cancer Epidemiol, 2019, 62:101582.
[7] WU Y D, SUN X J, SONG B, et al. MiR-375/SLC7A11 Axis regulates oral squamous cell carcinoma proliferation and invasion[J]. Cancer Med, 2017, 6(7):1686-1697.
[8] ZHANG R R, POINTER K B, KUO J S. Excitotoxic SLC7A11 expression is a marker of poor glioblastoma survival and a potential therapeutic target[J]. Neurosurgery, 2015, 77(6):N16-N17.
[9] JI X M, QIAN J, RAHMAN S M J, et al. xCT (SLC7A11)-mediated metabolic reprogramming promotes non-small cell lung cancer progression[J]. Oncogene, 2018, 37(36):5007-5019.
[10] RHODES D R, YU J J, SHANKER K, et al. ONCOMINE:a cancer microarray database and integrated data-mining platform[J]. Neoplasia, 2004, 6(1):1-6.
[11] TANG Z F, LI C W, KANG B X, et al. GEPIA:a web server for cancer and normal gene expression profiling and interactive analyses[J]. Nucleic Acids Res, 2017, 45(W1):W98-W102.
[12] FRANZ M, RODRIGUEZ H, LOPES C, et al. GeneMANIA update 2018[J]. Nucleic Acids Res, 2018, 46(W1):W60-W64.
[13] WARDE-FARLEY D, DONALDSON S L, COMES O, et al. The GeneMANIA prediction server:biological network integration for gene prioritization and predicting gene function[J]. Nucleic Acids Res, 2010, 38(Web Server issue):W214-W220.
[14] KANEHISA M, FURUMICHI M, TANABE M, et al. KEGG:new perspectives on genomes, pathways, diseases and drugs[J]. Nucleic Acids Res, 2017, 45(D1):D353-D361.
[15] KANEHISA M, SATO Y, FURUMICHI M, et al. New approach for understanding genome variations in KEGG[J]. Nucleic Acids Res, 2019, 47(D1):D590-D595.
[16] CONRAD M, SATO H. The oxidative stress-inducible cystine/glutamate antiporter, system x (c) (-):cystine supplier and beyond[J]. Amino Acids, 2012, 42(1):231-246.
[17] ROBERT S M, BUCKINGHAM S C, CAMPBELL S L, et al. SLC7A11 expression is associated with seizures and predicts poor survival in patients with malignant glioma[J]. Sci Transl Med, 2015, 7(289):289ra86.
[18] MA Z H, ZHANG H, LIAN M, et al. SLC7A11, a component of cysteine/glutamate transporter, is a novel biomarker for the diagnosis and prognosis in laryngeal squamous cell carcinoma[J]. Oncol Rep, 2017, 38(5):3019-3029.
[19] SHIOZAKI A, ⅡTAKA D, ICHIKAWA D, et al. xCT, component of cysteine/glutamate transporter, as an independent prognostic factor in human esophageal squamous cell carcinoma[J]. J Gastroenterol, 2014, 49(5):853-863.
[20] GAO M H, MONIAN P, QUADRI N, et al. Glutaminolysis and transferrin regulate ferroptosis[J]. Mol Cell, 2015, 59(2):298-308.
[21] DAHLMANNS M, YAKUBOV E, CHEN D S, et al. Chemotherapeutic xCT inhibitors sorafenib and erastin unraveled with the synaptic optogenetic function analysis tool[J]. Cell Death Discov, 2017, 3:17030.
[22] WADA F, KOGA H, AKIBA J, et al. High expression of CD44v9 and xCT in chemoresistant hepatocellular carcinoma:Potential targets by sulfasalazine[J]. Cancer Sci, 2018, 109(9):2801-2810.
[23] LIN C H, LIN P P, LIN C Y, et al. Decreased mRNA expression for the two subunits of system xc(-), SLC3A2 and SLC7A11, in WBC in patients with schizophrenia:Evidence in support of the hypo-glutamatergic hypothesis of schizophrenia[J]. J Psychiatr Res, 2016, 72:58-63.
[24] CHEN L, CUI H M. Targeting glutamine induces apoptosis:a cancer therapy approach[J]. Int J Mol Sci, 2015, 16(9):22830-22855.
[25] HENSLEY C T, WASTI A T, DEBERARDINIS R J. Glutamine and cancer:cell biology, physiology, and clinical opportunities[J]. J Clin Invest, 2013, 123(9):3678-3684.
[26] WALKER D K, DRUMMOND M J, DICKINSON J M, et al. Insulin increases mRNA abundance of the amino acid transporter SLC7A5/LAT1 via an mTORC1-dependent mechanism in skeletal muscle cells[J]. Physiol Rep, 2014, 2(3):e00238.

数据挖掘分析SLC7A11在食管癌中的表达及通过P53/ROS通路调节细胞铁死亡的意义

Data mining analysis of SLC7A11 expression in esophageal cancer and its involvement in regulating ferroptosis through the P53/ROS Metabolic Pathway

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	张玉领, 陈培. 环状RNA在食管癌中的研究进展[J]. 癌变·畸变·突变, 2021, 33(3): 241-245.
[2]	张娜, 范志露, 杨荔艳, 常晨, 蔡岩, 郝佳洁, 王明荣. 食管鳞癌中SERPINB5表达降低的作用机制及其临床意义[J]. 癌变·畸变·突变, 2021, 33(2): 101-109.
[3]	焦文静, 郭秀娟, 马鸣, 邵俊国, 张金艳. 老年局部晚期食管癌同步放化疗与单纯放疗的疗效比较[J]. 癌变·畸变·突变, 2021, 33(2): 124-128.
[4]	陈婉娴, 王思梦, 陈张瑜, 王潘集, 郑淳文, 李恩民, 许丽艳. CDC42抑制剂CASIN对食管癌细胞活力与迁移能力的抑制作用[J]. 癌变·畸变·突变, 2021, 33(2): 136-142.
[5]	李玮玮, 朱莹. 数据挖掘分析MYB家族在乳腺癌中的表达及其预后评估价值[J]. 癌变·畸变·突变, 2020, 32(6): 414-422.
[6]	张力, 张爱华, 王文娟. 甲基汞暴露致学习记忆功能障碍作用机制的研究进展[J]. 癌变·畸变·突变, 2020, 32(6): 490-493.
[7]	杨丽, 张孟贤, 张微, 熊英友, 陈世勇, 方呈祥. 基于数据挖掘分析极光激酶A在食管癌中的表达及意义[J]. 癌变·畸变·突变, 2020, 32(3): 221-228.
[8]	郭倪君, 林忠宁, 林育纯. 铁死亡信号介导抗肿瘤作用的细胞器调控机制研究进展[J]. 癌变·畸变·突变, 2020, 32(2): 149-154.
[9]	封敏, 艾比拜·莫合塔尔, 石静怡, 祖可来·艾力江, 李永祥, 闫长顺, 李秀梅. 哈萨克族食管癌组织中miR-143、miR-145和Survivin mRNA的表达及其临床病理意义[J]. 癌变·畸变·突变, 2020, 32(1): 29-32.
[10]	马莉莉, 张树丽, 李琴, 许彭, 封敏, 李秀梅. 新疆哈萨克族食管癌与正常组织间差异表达miRNA的筛查及验证[J]. 癌变·畸变·突变, 2020, 32(1): 52-56.
[11]	孙晓男, 苑青, 杨荔艳, 张钰, 蔡岩, 徐昕, 王明荣, 郝佳洁, 贾雪梅. 成纤维细胞生长因子结合蛋白2过表达促进食管癌细胞的增殖[J]. 癌变·畸变·突变, 2019, 31(3): 180-185,192.
[12]	陈欣然, 宋永志, 单保恩. 协同刺激分子B7-H4在食管癌前病变组织中的表达及临床意义[J]. 癌变·畸变·突变, 2018, 30(5): 368-373.
[13]	杨兴肖, 邹乃祎, 李巧芳, 张雪原, 宋姮, 刘志坤, 马鸣, 单保恩, 祝淑钗. RNF2和PCNA在食管鳞状细胞癌中的表达及临床意义[J]. 癌变·畸变·突变, 2018, 30(4): 254-257.
[14]	陈欣然, 单保恩. 协同刺激分子B7-H4在小鼠食管癌前病变中的表达[J]. 癌变·畸变·突变, 2018, 30(4): 263-269,274.
[15]	何曙芝, 赵跃, 刘洋, 杨留才, 陈平, 刘冉. 盐城地区食管癌化疗患者近期生命质量评价[J]. 癌变·畸变·突变, 2017, 29(6): 437-444,449.